Kazia Therapeutics Announces Filing of Annual Report on Form 20-F for Fiscal Year Ended June 30, 2026
PR Newswire•19/11/2026•07:00 ET
1
Key Highlights
- ➤Stage IV TNBC data: 83% objective response rate across six evaluable patients
- ➤Cash, equivalents and short-term investments totaled approximately A$61.2 million
- ➤Public offering targets up to US$120 million, including US$40 million upfront
- ➤Sovargen trial milestone triggered a US$2 million payment to Kazia
- ➤Colorectal cancer Phase 2 enrollment expected to commence in Q1 2027
Kazia Therapeutics Announces Filing of Annual Report on Form 20-F for Fiscal Year Ended June 30, 2026 PR Newswire
SYDNEY, Nov. 19, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, today announced that it has filed its Annual Report on Form 20-F for the fiscal year ended June 30, 2026 with the U.S. Securities and Exchange Commission ("SEC").
Get started
Create a free account to read the full story.
